[ Inside the business ]

LIN stock analysis

LIN · Linde Plc

Industrial inorganic chemicals. Growing 9%.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.6× sales in 5 yrs. Evidence: backlog of 1.8× sales · sales +9% · 25¢ profit/$1.

01 What's priced in?2.6× sales in 5 yrs
Sales now$36.2B
Needed in 5 yrs$93.1B
Backlog$66.0B
02 Is the wave rising?Clean hydrogen · 0.6×
'20'21'22'23'24'2579
#8 of 20 mentioning it
03 Will customers keep buying?Sales +9%, steady
No customer over 10%
Backlog $66.0B · 1.8× salesPrepaid $2.4BSales +9%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 25¢ per $1
'21'22'23'24'2525¢
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.1%/yrDebt $26.4B
07 What could break it?3 to watch
  • Growth peaked
  • Insiders sold $50M outside pre-set plans
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +8%, +9%, then +9% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.7× the market. In the 2008 crisis it fell 32% while the market fell 51%. Debt is moderate.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

45% Americas Segment.

Americas Segment 45% · EMEA Segment 25% · APAC Segment 20% · Engineering Segment 6% · other

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.1× the economy.

The government expects its industry, chemical manufacturing, to grow 2.2% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 153¢ of each $1 of profit.

Competitive advantage

5 of 10 years.

Returns beat its 7.6% cost of capital in 5 of the last 10 years.

Future bets

0% on research.

$147M a year on R&D. $5.6B on equipment and buildings.

All figures from Linde Plc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.